| clinical trial | Q30612 |
| P3098 | ClinicalTrials.gov ID | NCT00918385 |
| P6099 | clinical trial phase | phase II clinical trial | Q42824440 |
| P767 | contributor to the creative work or subject | Bristol-Myers Squibb | Q266423 |
| P17 | country | United States of America | Q30 |
| P582 | end time | 2012-02-01 | |
| P921 | main subject | metastatic prostate carcinoma | Q55779807 |
| P2899 | minimum age | 18 | |
| P1132 | number of participants | 57 | |
| P4844 | research intervention | dasatinib | Q419940 |
| P6153 | research site | University of Washington | Q219563 |
| Duke University Medical Center | Q30279912 | ||
| Oregon Health & Science University | Q282097 | ||
| P1813 | short name | ARS | |
| P580 | start time | 2009-05-01 | |
| P8363 | study type | interventional study | Q78089383 |
| P1476 | title | A Phase II Trial of Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer |
Search more.